Our site uses cookies to make navigation as function as possible, including “third party” cookies and “profiling cookies” designed to tailor
on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your
consent to some or all cookies, click here. If you proceed with browsing this website, you will be consenting to the use of all cookies.


该基金会成立于 1976 年...






May 16 2023

Menarini presents in Florence its latest art monograph, dedicated to the symbol of the Italian Renaissance

Read More
April 13 2023

The Dates of the XXVII Edition of the International Fair Play Menarini Awards

Read More
January 30 2023

Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer

Read More
September 20 2022

美纳里尼与赛生药业签署独家许可协议 - 在华开发和商业化Vaborem®以治疗耐药菌感染

Read More
August 24 2022

Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced Metastatic Breast Cancer

Read More